Should immunotherapy be standard of care for metastatic MSI-high colorectal cancer?
Does the recent Hopkins trial of pembrolizumab change your management of these patients?
Answer from: Medical Oncologist at Academic Institution
It should be a treatment option but not yet in the first line. My first option for MSI-H patients is to enroll in an immunotherapy trial. If not available, I'll usually reserve single-agent PD-1 inhibitors until after second line therapy. Recent data suggests that the Ipilimumab-nivolumab comb...
Sign in or Register to read more